PSMA PET- and mpMRI-directed Prostate Cancer Salvage - ScienceDirect

PSMA PET- and mpMRI-directed Prostate Cancer Salvage - ScienceDirect

We congratulate Raman et al on their analysis of patients who received restaging 18F-DCFPyL positron emission spectroscopy (PET) for biochemical recurrence (BR) after primary brachytherapy.

Seventy of 73 patients (96%) who received PET for BR after low-dose-rate (LDR) monotherapy had a true positive PET, and 38 of 70 patients (54%) had isolated local recurrence. Furthermore, most intraprostatic recurrences (69%) were in the same sextant as the original diagnostic biopsy results. These findings suggest a potential role for local salvage therapies.

 

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News